JPH026328B2 - - Google Patents
Info
- Publication number
- JPH026328B2 JPH026328B2 JP10620382A JP10620382A JPH026328B2 JP H026328 B2 JPH026328 B2 JP H026328B2 JP 10620382 A JP10620382 A JP 10620382A JP 10620382 A JP10620382 A JP 10620382A JP H026328 B2 JPH026328 B2 JP H026328B2
- Authority
- JP
- Japan
- Prior art keywords
- background background
- animals
- humans
- infections
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 208000035473 Communicable disease Diseases 0.000 claims description 12
- 208000026278 immune system disease Diseases 0.000 claims description 10
- 230000003449 preventive effect Effects 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 229920001550 polyprenyl Polymers 0.000 claims description 3
- 125000001185 polyprenyl group Polymers 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 19
- 208000015181 infectious disease Diseases 0.000 description 19
- 229940079593 drug Drugs 0.000 description 15
- 241000282412 Homo Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000843 powder Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- -1 ketone compounds Chemical class 0.000 description 7
- 244000144972 livestock Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 229940099112 cornstarch Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000007123 defense Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OJADOGDELNTUGN-UHFFFAOYSA-N (all-E)-6,10,14,18,22,26,30-heptamethyl-hentriaconta-5,9,13,17,21,25,29-heptaen-2-one Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=O OJADOGDELNTUGN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- HNZUNIKWNYHEJJ-FMIVXFBMSA-N geranyl acetone Chemical compound CC(C)=CCC\C(C)=C\CCC(C)=O HNZUNIKWNYHEJJ-FMIVXFBMSA-N 0.000 description 1
- HNZUNIKWNYHEJJ-UHFFFAOYSA-N geranyl acetone Natural products CC(C)=CCCC(C)=CCCC(C)=O HNZUNIKWNYHEJJ-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- KTGKDWJBRNYLBP-UHFFFAOYSA-N n-C31-Alkan-2-one Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(C)=O KTGKDWJBRNYLBP-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、免疫機能不全による疾患の予防・治
療剤、特に感染症に対する防禦剤に関する。更に
詳しく述べれば、
一般式
（式中ａ、ｂは水素原子またはａ−ｂで結合手を
形成する。ｎは１〜10の整数を意味する。）
で表わされるポリプレニルケトンを有効成分とす
るヒトまたは動物の免疫機能不全による疾患の予
防・治療剤、特にヒトまたは動物の感染症に対す
る防禦剤に関する。
近年、免疫学の進歩が急速であり、種々の疾患
が免疫機能不全に起因しているものと考えられて
きている。例えば、癌、細菌感染症、喘息、関節
リウマチ、自己免疫疾患などが免疫機能不全に起
因している疾患としてあげられている。
細菌感染症は、単に病原菌の浸入のみによる単
純性感染症に加えて、各種重篤な基礎疾患を伴う
複雑性感染症の増加が深刻な問題となつてきてい
る。例えば癌に伴う感染症は臨床上最もわずらわ
しい問題である。癌を担うことによつて、全身
性、局所的な抵抗力低下を招き、易感染状態下で
感染症を合併、続発する。癌に伴う感染は、初期
においては呼吸器感染、尿路感染、胎道感染、皮
膚感染が多く、末期においては肺炎、敗血症が多
い。この腫瘍に伴う感染症併発の機序について
は、次のような過程が一般的である。
すなわち、白血病、悪性リンパ腫、癌の進展に
伴い、正常な組織、細胞の障害、特にリンパ系細
胞や、顆粒球細胞機能の低下をきたすので、易感
染性となり、感染症を併発すると考えられてい
る。このような場合、抗生剤投与による根治効果
が乏しく、反復感染、菌交代症、難治感染にいた
ることが多い。したがつて、従来の抗生剤、化学
療法剤のみでは根治がほとんど期待できず、生体
防禦機能の改善なくしては治療不可能であり、生
体の防禦機能を高める薬剤の開発が望まれてい
る。
一方、家畜・家禽などの動物の細菌感染に対し
ては、抗生物質がその中心的存在となつており、
事実、各種の抗生物質の登場によつて病原細菌に
よる重篤な感染症は減少している。しかし、畜産
界では抗菌剤の乱用から、畜水産物中の残留・耐
性菌の増加、菌交代症などを引き起こし、社会問
題となつている。すなわち、宿主は感染防禦能が
著しく低下し、感染症に対する修復機能も障害さ
れているため、細菌感染症は直りにくく再感染し
易い状態を作つている。更に、自発性感染症（日
和見感染症）が家畜の生産性を低下させ、その損
失は大きい。そこで宿主の免疫能の活性を高め、
生体の防禦機能を高める必要がある。
本発明者等は、上述の実情に鑑み、免疫機能を
正常化し、生体の防禦機能を高める薬剤につい
て、長年鋭意研究してきたが、意外にも
次の一般式
（式中ａ、ｂは水素原子またはａ−ｂで結合手を
形成する。ｎは１〜10の整数を意味する。）
で表わされるポリプレニルケトン系化合物が、ヒ
トおよび動物の免疫機能不全による疾患の予防・
治療剤、特にヒトおよび動物の感染症に対する防
禦剤として有効であることを見い出し、本発明を
完成したものである。
すなわち、本発明化合物は、ヒトおよび動物の
免疫機能を正常化し、感染抵抗性を高める作用を
有するので、ヒトおよび動物の免疫機能不全によ
る疾患の予防・治療剤、各種感染症に対する防禦
剤として有用である。
ヒトの場合の具体例をあげれば、関節リウマ
チ、自己免疫疾患、癌、喘息、および例えば敗血
症、肺炎、髄膜炎、各種ウイルス感染症などの各
種感染症などに有効である。
また動物の場合の具体例をあげれば、例えば豚
の下痢、肺炎（SEP、AR、ヘモフイルス、パス
ツレラ）、TGE、鶏の肺炎（マイクロプラズマ、
ヘモフイルス）、マレツク病、牛の下痢、肺炎、
乳房炎などに有効である。
また、ヒトおよび動物の感染症に本発明化合物
を投与する場合、抗生物質との併用により著しく
その治療効果を高める。このことは、前述した畜
産業界で問題となつている抗生物質の乱用という
問題をも解決するものであり重要な意義がある。
更に、家畜・家禽などの動物の場合を例にとれ
ば、生体の感染抵抗性を高めるので、初生時のベ
ース薬として有用であること、多頭羽飼育、輸送
などに起因するストレスの緩和に有用であるこ
と、およびワクチン効果の増強に有用である。
したがつて、本発明の目的は、ヒトおよび動物
の免疫機能不全の新規な予防・治療剤を提供する
にある。
更に、本発明の目的は、ヒトおよび動物の感染
症に対する新規な防禦剤を提供するにある。
本発明におけるポリプレニルケトン系化合物の
代表的化合物を以下に掲げるが、本発明がこれら
のものに限定されることがないことはいうまでも
ない。
Γ６，10，14−トリメチル−５，９，13−ペンタ
デカトリエン−２−オン
Γ６，10，14，18−テトラメチル−５，９，13，
17−ノナデカテトラエン−２−オン
Γ６，10，14，18，22−ペンタメチル−５，９，
13，17，21−トリコサペンタエン−２−オン
Γ６，10，14，18，26−ヘキサメチル−５，９，
13，17，21，25−ヘプタコサヘキサエン−２−
オン
Γ６，10，14，18，22，26，30−ヘプタメチル−
５，９，13，17，21，25，29−ヘントリアコン
タヘプタエン−２−オン
Γ６，10，14，18，22，26，30，34−オクタメチ
ル−５，９，13，17，21，25，29，33−ペンタ
トリアコンタオクタエン−２−オン
Γ６，10，14，18，22，26，30，34，38−ノナメ
チル−５，９，13，17，21，25，29，33，37，
−ノナトリアコンタノナエン−２−オン
Γ６，10，14，18，22，26，30，34，38，42−デ
カメチル−５，９，13，17，21，25，29，33，
37，41−トリテトラコンタデカエン−２−オン
Γ６，10−ジメチル−５，９−ウンデカジエン−
２−オン
Γ６−メチル−５−ヘプタエン−２−オン
Γ６，10，14，18，22，26，30，34，38，42−デ
カメチルトリテトラコンタン−２−オン
Γ６，10，14，18，22，26，30，34，38−ノナメ
チルノナトリアコンタン−２−オン
Γ６，10，14，18，22，26，30，34−オクタメチ
ルペンタトリアコンタン−２−オン
Γ６，10，14，18，22，26，30−ヘプタメチル−
ヘントリアコンタン−２−オン
Γ６，10，14，18，22，26−ヘキサメチルヘプタ
コサン−２−オン
Γ６，10，14，18，22−ペンタメチルトリコサペ
ンタン−２−オン
Γ６，10，14，18−テトラメチルノナデカン−２
−オン
Γ６，10，14−トリメチルペンタデカン−２−オ
ン
Γ６，10−ジメチルウンデカン−２−オン
Γ６−メチルヘプタン−２−オン
本発明化合物は、種々の方法で合成されるが、
これらの方法のうち通常の方法の一つを以下に述
べる。
（式中ａ、ｂおよびｎは前記の意味を有し、Ｘは
ハロゲン原子を示す。）
すなわち、一般式（）で示されるプレニルハ
ライドと、アセト酸酸エチルエステル（）を金
属ナトリウム、金属カリウム、ナトリウムエチラ
ート、ナトリウムハイドラート等の縮合剤の存在
下で、必要ならば、エタノール、ｔ−ブタノー
ル、ジオキサン、ベンゼン等の溶媒を使用し、縮
合せしめ、得られた縮合生成物（）に通常これ
を単離することなく、稀苛性ソーダ水溶液、稀苛
性カリ水溶液等のアルカリ試薬で処理し、エステ
ル開裂、脱炭酸せしめて目的物質を得ることがで
きる。
次に本発明化合物の効果を実験例にて詳述す
る。
実験例
１ 感染防禦効果
(1) 実験方法
slc：ICR雄性マウス（６〜７週令、体重
22〜30ｇ）に、下記に記載した被験化合物を
次表（表１）に示す量筋肉内投与し、24時間
後に臨床由来の大腸菌（Escherichia Ccli）
を2.8×108／マウスを皮下接種し、感染後７
日目の生存数から生残率を求めた。
(2) 被験化合物
６，10，14，18，22，26−ヘキサメチル−
５，９，13，17，21，25−ヘプタコサヘキサ
ン−２−オン
６，10，14，18，22，26，30−ヘプタメチ
ル−５，９，13，17，21，25，29−ヘントリ
アコンタヘプタエン−２−オン
６，10−ジメチル−５，９−ウンデカジエ
ン−２−オン
６，10，14，18，22，26，30，34，38，42
−デカメチル−５，９，13，17，21，25，
29，33，37，41−トリテトラコンタデカエン
−２−オン
６，10−ジメチルウンデカン−２−オン
６，10，14−トリメチルペンタデカン−２
−オン
６，10，14，18，22，26，30，34，38，42
−デカメチルトリテトラコンタン−２−オン
対照化合物：MDP（AcMur−Ｌ−Ala−Ｄ
−Glu）
(3) 実験結果
結果を表１に示す。
The present invention relates to preventive and therapeutic agents for diseases caused by immune dysfunction, particularly to preventive agents against infectious diseases. In more detail, the general formula (In the formula, a and b form a bond with a hydrogen atom or a-b. n means an integer from 1 to 10.) Immune dysfunction in humans or animals using polyprenyl ketone as an active ingredient The present invention relates to preventive/therapeutic agents for diseases caused by infectious diseases, particularly to preventive agents against infectious diseases in humans or animals. In recent years, advances in immunology have been rapid, and various diseases are thought to be caused by immune dysfunction. For example, cancer, bacterial infections, asthma, rheumatoid arthritis, autoimmune diseases, and the like are listed as diseases caused by immune dysfunction. BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND BACKGROUND OF THE INVENTION Bacterial infections are becoming a serious problem, with an increase in complex infections accompanied by various serious underlying diseases, in addition to simple infections caused solely by infiltration of pathogenic bacteria. For example, infectious diseases associated with cancer are one of the most troublesome clinical problems. Carrying cancer leads to a decrease in systemic and local resistance, leading to complications and subsequent infections in immunocompromised conditions. Infections associated with cancer often include respiratory tract infections, urinary tract infections, fetal canal infections, and skin infections in the early stages, and pneumonia and sepsis in the late stages. The following process is the general mechanism of infection associated with this tumor. In other words, as leukemia, malignant lymphoma, and cancer progress, they cause damage to normal tissues and cells, especially lymphoid cells and granulocyte cell function, which makes them susceptible to infection and is thought to cause infections. There is. In such cases, antibiotic administration has little curative effect, often leading to repeated infections, bacterial replacement, and intractable infections. Therefore, conventional antibiotics and chemotherapeutic agents alone cannot be expected to provide a complete cure, and treatment is not possible without improving the body's defense function, and there is a desire for the development of drugs that enhance the body's defense function. On the other hand, antibiotics play a central role in treating bacterial infections in animals such as livestock and poultry.
In fact, with the advent of various antibiotics, serious infections caused by pathogenic bacteria are decreasing. However, in the livestock industry, overuse of antibacterial agents has caused an increase in residual and resistant bacteria in livestock and marine products, as well as bacterial replacement disease, which has become a social problem. In other words, the host's ability to defend against infection is significantly reduced and its repair function against infection is impaired, creating a state in which bacterial infections are difficult to cure and reinfection is easy to occur. Furthermore, spontaneous infections (opportunistic infections) reduce the productivity of livestock, resulting in large losses. Therefore, it increases the activity of the host's immune system,
It is necessary to enhance the defense function of the living body. In view of the above-mentioned circumstances, the present inventors have been conducting intensive research for many years on drugs that normalize the immune function and enhance the defense function of the living body, but unexpectedly found the following general formula. (In the formula, a and b form a bond with a hydrogen atom or a-b. n means an integer from 1 to 10.) Disease prevention/
The present invention was completed based on the discovery that the present invention is effective as a therapeutic agent, particularly as a preventative against infectious diseases in humans and animals. That is, the compound of the present invention has the effect of normalizing the immune function of humans and animals and increasing resistance to infection, and is therefore useful as a prophylactic/therapeutic agent for diseases caused by immune dysfunction in humans and animals, and as a preventive agent against various infectious diseases. It is. To give specific examples in humans, it is effective against rheumatoid arthritis, autoimmune diseases, cancer, asthma, and various infectious diseases such as sepsis, pneumonia, meningitis, and various viral infections. Specific examples for animals include diarrhea in pigs, pneumonia (SEP, AR, Haemophilus, pasteurella), TGE, pneumonia in chickens (microplasma,
haemophilus), Maretske's disease, bovine diarrhea, pneumonia,
It is effective for mastitis, etc. Furthermore, when the compounds of the present invention are administered to treat infectious diseases in humans and animals, their therapeutic effects are significantly enhanced when used in combination with antibiotics. This is of great significance as it also solves the aforementioned problem of overuse of antibiotics in the livestock industry. Furthermore, in the case of animals such as livestock and poultry, it increases the organism's resistance to infection, so it is useful as a base drug at the beginning of life, and it is useful for alleviating stress caused by raising multiple birds and transporting them. and is useful for enhancing vaccine efficacy. Therefore, an object of the present invention is to provide a novel prophylactic/therapeutic agent for immune dysfunction in humans and animals. A further object of the present invention is to provide a novel protective agent against infectious diseases in humans and animals. Typical polyprenyl ketone compounds in the present invention are listed below, but it goes without saying that the present invention is not limited to these. Γ6,10,14-trimethyl-5,9,13-pentadecatrien-2-one Γ6,10,14,18-tetramethyl-5,9,13,
17-nonadecatetraen-2-one Γ6,10,14,18,22-pentamethyl-5,9,
13,17,21-tricosapentaen-2-one Γ6,10,14,18,26-hexamethyl-5,9,
13,17,21,25-heptacosahexaene-2-
on Γ6,10,14,18,22,26,30-heptamethyl-
5,9,13,17,21,25,29-hentriacontaheptaen-2-one Γ6,10,14,18,22,26,30,34-octamethyl-5,9,13,17,21 , 25, 29, 33-pentatriacontaoctaen-2-one Γ6, 10, 14, 18, 22, 26, 30, 34, 38-nonamethyl-5, 9, 13, 17, 21, 25, 29, 33, 37,
-nonatriacontanonaen-2-one Γ6, 10, 14, 18, 22, 26, 30, 34, 38, 42-decamethyl-5, 9, 13, 17, 21, 25, 29, 33,
37,41-tritetracontadecaen-2-one Γ6,10-dimethyl-5,9-undecadiene-
2-one Γ6-methyl-5-heptaen-2-one Γ6,10,14,18,22,26,30,34,38,42-decamethyltritetracontan-2-one Γ6,10,14,18 ,22,26,30,34,38-Nonamethylnonatriacontan-2-one Γ6,10,14,18,22,26,30,34-Octamethylpentatriacontan-2-one Γ6,10,14 ,18,22,26,30-heptamethyl-
hentriacontan-2-one Γ6,10,14,18,22,26-hexamethylheptacosan-2-one Γ6,10,14,18,22-pentamethyltricosapentan-2-one Γ6,10, 14,18-tetramethylnonadecane-2
-one Γ6,10,14-trimethylpentadecane-2-one Γ6,10-dimethylundecane-2-one Γ6-methylheptan-2-one The compound of the present invention can be synthesized by various methods, but
One of the common methods will be described below. (In the formula, a, b and n have the above-mentioned meanings, and X represents a halogen atom.) That is, the prenyl halide represented by the general formula () and the acetic acid ethyl ester () are combined with metal sodium and metal potassium. Condensation is carried out in the presence of a condensing agent such as , sodium ethylate, or sodium hydrate, using a solvent such as ethanol, t-butanol, dioxane, or benzene, if necessary, and the resulting condensation product () is usually Without isolating this, it can be treated with an alkaline reagent such as a dilute aqueous caustic soda solution or a dilute aqueous caustic potassium solution to cause ester cleavage and decarboxylation to obtain the target substance. Next, the effects of the compounds of the present invention will be explained in detail using experimental examples. Experimental Example 1 Infection prevention effect (1) Experimental method slc: ICR male mice (6-7 weeks old, body weight
The test compound described below was administered intramuscularly in the amount shown in the following table (Table 1) to 22 to 30 g), and 24 hours later, Escherichia Ccli of clinical origin was administered.
2.8 × 10 8 /mouse were inoculated subcutaneously, and 7 days after infection.
The survival rate was calculated from the number of survivors on the day. (2) Test compound 6,10,14,18,22,26-hexamethyl-
5,9,13,17,21,25-heptacosahexan-2-one 6,10,14,18,22,26,30-heptamethyl-5,9,13,17,21,25,29-hentriacontaheptaen-2-one 6,10-dimethyl-5,9-undecadien-2-one 6, 10, 14, 18, 22, 26, 30, 34, 38, 42
-decamethyl-5,9,13,17,21,25,
29,33,37,41-tritetracontadecaen-2-one 6,10-dimethylundecane-2-one 6,10,14-trimethylpentadecane-2
−on 6, 10, 14, 18, 22, 26, 30, 34, 38, 42
-decamethyltritetracontan-2-one Control compound: MDP (AcMur-L-Ala-D
-Glu) (3) Experimental results The results are shown in Table 1.
【表】
２ マクロフアージの貪食能の増大効果
(1) 実験方法および結果
slc：ICR系雄性マウス（８週令、体重22
〜30ｇ）に、前記した被験化合物を100mg／
Kg筋肉内投与し、24時間後にカーボン・クリ
アランステストをおこない、マクロフアージ
の貪食能を測定した。なおカーボン・クリア
ランステストは、G.BIOZZI、B.
BENACERRAF AND B.N.HALPERN、
Brit.J.exp.Path.、34441−457に記載されて
いる方法に準じておこなつた。具体的に述べ
れば以下の方法で行つたカーボン・クリアラ
ンステストはコロイドカーボンの血中からの
クリアランスを指標として肝、脾のマクロフ
アージ機能を測定するものである。
Gu¨nter Wagner社製のカーボンを160mg／
Kgの割合でマウス尾静脈内に注入した。注入
後、１、４、７、10、13分後に後眼窩静脈叢
より20μを採血し、小試験管中で２mlの0.1
％炭酸ナトリウムと混合した。これについて
660nMの波長で吸光度を測定した。
横軸に時間（分）を、縦軸に吸光度の対数
値をとり、３分毎の値プロツトする。この直
線の勾配を求めて半減時間を算出した。
Control群の半減時間を100として、それに対
する各被験化合物の半減時間の割合を比較し
た（数値が小さくなつていればマクロフアー
ジの亢進を示す）。
その結果を表２に示す。
表２において、貪食能の変化（％）の数値
は、コントロールの半減時間を100とし、こ
れに対して変化した割合を示す。[Table] 2 Effect of macrophages on increasing phagocytosis (1) Experimental methods and results slc: ICR male mice (8 weeks old, body weight 22
~30g) of the test compound described above at 100mg/
Kg was administered intramuscularly, and 24 hours later, a carbon clearance test was performed to measure the phagocytic ability of macrophages. The carbon clearance test was conducted by G.BIOZZI, B.
BENACERRAF AND BNHALPERN,
It was carried out according to the method described in Brit.J.exp.Path., 34441-457. Specifically, the carbon clearance test conducted by the following method measures the macrophage function of the liver and spleen using the clearance of colloidal carbon from the blood as an index. 160 mg of Gunter Wagner carbon
Kg was injected into the mouse tail vein. 1, 4, 7, 10, and 13 minutes after injection, 20μ of blood was collected from the retroorbital venous plexus, and 2ml of 0.1
% sodium carbonate. about this
Absorbance was measured at a wavelength of 660nM. The horizontal axis represents time (minutes), the vertical axis represents the logarithm of absorbance, and the values are plotted every 3 minutes. The half-life time was calculated by finding the slope of this straight line.
The half-life time of the control group was set as 100, and the ratio of the half-life time of each test compound to that was compared (a smaller value indicates enhancement of macrophage). The results are shown in Table 2. In Table 2, the numerical value of change (%) in phagocytosis indicates the percentage of change relative to the control half-life time of 100.
【表】
表２において、貪食能力が高まつている場合
は、半減時間が減少するが、20％以上、すなわち
その数値が80より少ない場合は強い貪食能の促進
を示す。したがつて、本発明化合物の代表化合物
である化合物ＡおよびＢは非常に強い貪食能の促
進効果があることが明らかである。
上記の実験例により、本発明化合物は免疫機能
を正常化し、感染抵抗性を高めることが明らかと
なつた。
本発明化合物は、極めて毒性の低いものであ
り、安全性は非常に高いものであり、したがつて
長期連用投与が可能であり、この意味でも本発明
の価値は高い。
すなわち、SD系ラツト（体重約200ｇ）に本発
明の代表的化合物である前記の化合物（化合物Ａ
〜Ｇ）を500mg／Kgを経口投与したが、死亡例、
副作用は何ら観察されなかつた。
本発明化合物をヒトの免疫機能不全による疾患
の予防・治療剤、あるいはヒトの感染症に対する
防禦剤として患者に投与する際の投与量は、疾患
の種類、症状の程度、化合物の種類などにより大
きく異なり特に限定されないが、成人１日あたり
約10mg〜4000mg、好ましくは50mg〜500mgを経口
若しくは非経口的に投与する。感染症に対する防
禦剤として投与する場合、抗生物質との併用はも
ちろんさしつかえない。投与剤型としては、例え
ば散剤、細粒剤、顆粒剤、錠剤、カプセル剤、注
射剤などがあげられる。製剤化の際は、通常の製
剤担体を用い、常法により製造する。
すなわち、経口用固形製剤を調製する場合は主
薬に賦形剤、更に必要に応じて結合剤、崩壊剤、
滑沢剤、着色剤、矯味矯臭剤などを加えた後、常
法により錠剤、被覆錠剤、顆粒剤、散剤、カプセ
ル剤などとする。
賦形薬としては、例えば乳糖、コーンスター
チ、白糖、ブドウ糖、ソルビツト、結晶セルロー
スなどが、結合剤としては例えば、ポリビニルア
ルコール、ポリビニールエーテル、エチルセルロ
ース、メチルセルロース、アラビアゴム、トラガ
ント、ゼラチン、シエラツク、ヒドロキシプロピ
ルセルロース、ヒドロキシプロピルスターチ、ポ
リビニルピロリドンなどが、崩壊剤としては例え
ば、デンプン、寒天、ゼラチン末、結晶セルロー
ス、炭酸カルシウム、炭酸水素ナトリウム、クエ
ン酸カルシウム、デキストリン、ペクチン等が、
滑沢剤としては例えば、ステアリン酸マグネシウ
ム、タルク、ポリエチレングリコール、シリカ、
硬化植物油等が、着色剤としては医薬品に添加す
ることが許可されているものが、矯味矯臭剤とし
ては、ココア末、ハツカ脳、芳香酸、ハツカ油、
竜脳、桂皮末等が用いられる。これらの錠剤、顆
粒剤には糖衣、ゼラチン衣、その他必要により適
宜コーテイングすることはもちろんさしつかえな
い。
注射剤を調製する場合には、主薬に必要により
PH調製剤、緩衝剤、安定化剤、保存剤、可溶化剤
などを添加し、常法により皮下、筋肉内、静脈内
用注射剤とする。
家畜、家禽などの動物に投与する際も、経口投
与若しくは非経口投与により投与する。経口投与
は通常飼料に添加しておこなう。また非経口投与
の例をあげれば、常法により注射剤を調製し、皮
下、筋肉内、静脈内などに投与する。
次に本発明化合物の代表的化合物である６，
10，14，18，22，26−ヘキサメチル−５，９，
13，17，21，25−ヘプタコサヘキサエン−２−オ
ン（以下主薬と称する）を有効成分とした製剤例
を示す。
製剤例 １
（カプセル剤）
主 薬 ５ｇ
微結晶セルローズ 80ｇ
トウモロコシデンプン 20ｇ
乳 糖 22ｇ
ポリビニルピロリドン ３ｇ
全 量 130ｇ
上記成分を常法により顆粒化したのち、ゼラチ
ン硬カプセル1000カプセルに充填した。１カプセ
ル中に主薬５mgを含有する。
製剤例 ２
（散剤）
主 薬 50ｇ
微結晶セルローズ 400ｇ
トウモロコシデンプン 550ｇ
全 量 1000ｇ
主薬をアセトンに溶解し、次いでこれを微結晶
セルローズに吸着させたのち、乾燥した。これを
トウモロコシデンプンと混合し、常法により散剤
として、主薬の20倍散を調製した。
製剤例 ３
（錠剤）
主 薬 ５ｇ
トウモロコシデンプン 10ｇ
乳 糖 20ｇ
カルボキシメチルセルローズカルシウム 10ｇ
微結晶セルローズ 40ｇ
ポリビニルピロリドン ５ｇ
タルク 10ｇ
全 量 100ｇ
主薬をアセトンに溶解し、次いでこれを微結晶
セルローズに吸着させたのち、乾燥した。これに
トウモロコシデンプン、乳糖、カルボキシメチル
セルローズカルシウムを混合し、次いでポリビニ
ルピロリドンの水溶液を結合剤として加えて常法
により顆粒化した。これに滑沢剤としてタルクを
加えて混合したのち、１錠100mgの錠剤に打錠し
た。１錠中には主薬５mgを含有する。
製剤例 ４
（注射剤）
主 薬 10ｇ
Nikkol HCO−60（日光ケミカル社製品名） 37ｇ
ゴマ油 ２ｇ
塩化ナトリウム ９ｇ
プロピレングリコール 40ｇ
リン酸緩衝液（0.1M.PH6.0） 100ｇ
蒸留水 全量1000ｇ
主薬、Nikkol HCO−60、ゴマ油および半量
のプロピレングリコールを混合して約80℃で加温
溶解し、これにリン酸緩衝液および塩化ナトリウ
ムとプロピレングリコールを予め溶解した蒸留水
を約80℃に加温して加え、全量1000mlの水溶液と
した。この水溶液を２mlのアンプルに分注して熔
閉したのち、加熱滅菌した。
１管中、主薬20mgを含有する。[Table] In Table 2, when the phagocytic ability is increased, the half-life time decreases, but when the value is 20% or more, that is, the value is less than 80, it indicates a strong promotion of the phagocytic ability. Therefore, it is clear that compounds A and B, which are representative compounds of the present invention, have a very strong phagocytosis-promoting effect. The above experimental examples revealed that the compound of the present invention normalizes immune function and increases resistance to infection. The compounds of the present invention have extremely low toxicity and are extremely safe, and therefore can be administered continuously over a long period of time, and in this sense, the value of the present invention is also high. That is, SD rats (body weight approximately 200 g) were given the above-mentioned compound (compound A), which is a representative compound of the present invention.
~G) was orally administered at 500 mg/Kg, but there were cases of death.
No side effects were observed. When administering the compound of the present invention to a patient as a prophylactic or therapeutic agent for diseases caused by human immune dysfunction or as a preventive agent against human infectious diseases, the dosage will vary depending on the type of disease, severity of symptoms, type of compound, etc. Although not particularly limited, the dose for adults is about 10 mg to 4000 mg, preferably 50 mg to 500 mg per day, administered orally or parenterally. When administered as a preventive agent against infectious diseases, it is of course possible to use it in combination with antibiotics. Examples of dosage forms include powders, fine granules, granules, tablets, capsules, and injections. When preparing a formulation, it is produced by a conventional method using a conventional pharmaceutical carrier. That is, when preparing oral solid preparations, excipients are added to the main drug, and if necessary, binders, disintegrants,
After adding lubricants, coloring agents, flavoring agents, etc., it is made into tablets, coated tablets, granules, powders, capsules, etc. by conventional methods. Excipients include, for example, lactose, cornstarch, sucrose, glucose, sorbitol, crystalline cellulose, etc. Binders include, for example, polyvinyl alcohol, polyvinyl ether, ethyl cellulose, methyl cellulose, gum arabic, tragacanth, gelatin, sierrac, and hydroxypropyl. Cellulose, hydroxypropyl starch, polyvinylpyrrolidone, etc., and disintegrants include starch, agar, gelatin powder, crystalline cellulose, calcium carbonate, sodium bicarbonate, calcium citrate, dextrin, pectin, etc.
Examples of lubricants include magnesium stearate, talc, polyethylene glycol, silica,
Hydrogenated vegetable oils, etc. are permitted to be added to pharmaceuticals as coloring agents, but as flavoring agents, cocoa powder, peppermint, aromatic acids, peppermint oil,
Dragon brain, cinnamon powder, etc. are used. Of course, these tablets and granules may be coated with sugar coating, gelatin coating, or other coatings as appropriate. When preparing injections, add as necessary to the main drug.
Add a PH adjuster, buffer, stabilizer, preservative, solubilizer, etc., and make it into a subcutaneous, intramuscular, or intravenous injection by a conventional method. When administering to animals such as livestock and poultry, the drug is administered orally or parenterally. Oral administration is usually done by adding it to feed. As an example of parenteral administration, an injection is prepared by a conventional method and administered subcutaneously, intramuscularly, intravenously, etc. Next, 6, which is a representative compound of the compounds of the present invention,
10,14,18,22,26-hexamethyl-5,9,
An example of a formulation containing 13,17,21,25-heptacosahexaen-2-one (hereinafter referred to as the active ingredient) as an active ingredient is shown below. Formulation Example 1 (Capsules) Main drug 5g Microcrystalline cellulose 80g Corn starch 20g Lactose 22g Polyvinylpyrrolidone 3g Total amount 130g The above ingredients were granulated by a conventional method and then filled into 1000 hard gelatin capsules. Each capsule contains 5mg of the active ingredient. Formulation Example 2 (Powder) Main drug 50g Microcrystalline cellulose 400g Corn starch 550g Total amount 1000g The main drug was dissolved in acetone, then adsorbed on microcrystalline cellulose, and then dried. This was mixed with corn starch and a 20-fold powder of the main drug was prepared as a powder using a conventional method. Formulation example 3 (tablet) Main drug 5g Corn starch 10g Lactose 20g Carboxymethylcellulose calcium 10g Microcrystalline cellulose 40g Polyvinylpyrrolidone 5g Talc 10g Total amount 100g The main drug was dissolved in acetone, and then adsorbed on microcrystalline cellulose. , dried. Corn starch, lactose, and carboxymethyl cellulose calcium were mixed therein, and then an aqueous solution of polyvinylpyrrolidone was added as a binder to form granules in a conventional manner. After adding talc as a lubricant and mixing, the mixture was compressed into tablets each weighing 100 mg. Each tablet contains 5mg of the active ingredient. Formulation example 4 (injection) Main drug 10g Nikkol HCO-60 (Nikkol Chemical Co., Ltd. product name) 37g Sesame oil 2g Sodium chloride 9g Propylene glycol 40g Phosphate buffer (0.1M.PH6.0) 100g Distilled water Total amount 1000g Main drug, Nikkol Mix HCO-60, sesame oil, and half the amount of propylene glycol, heat and dissolve at about 80℃, add phosphate buffer, sodium chloride, and distilled water with propylene glycol dissolved in advance, and heat to about 80℃. This was added to make a total volume of 1000 ml of an aqueous solution. This aqueous solution was dispensed into 2 ml ampoules, which were sealed and sterilized by heating. One tube contains 20mg of the main drug.
Claims (1)
形成する。ｎは１〜10の整数を意味する。） で表わされるポリプレニルケトンを有効成分とす
るヒトまたは動物の免疫機能不全による疾患の予
防・治療剤。 ヒトまたは動物の免疫機能不全による疾患の予
防・治療が、ヒトまたは動物の感染症に対する防
禦である特許請求の範囲第１項記載のヒトまたは
動物の免疫機能不全による疾患の予防・治療剤。[Claims] 1. General formula (In the formula, a and b form a bond with a hydrogen atom or a-b. n means an integer from 1 to 10.) Immune dysfunction in humans or animals using polyprenyl ketone as an active ingredient A preventive/therapeutic agent for diseases caused by 2. The preventive/therapeutic agent for diseases caused by immune dysfunction in humans or animals according to claim 1, wherein the prevention/treatment of diseases caused by immune dysfunction in humans or animals is protection against infectious diseases in humans or animals.
Priority Applications (40)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10620382A JPS58225014A (en) | 1982-06-22 | 1982-06-22 | Preventive and remedy for disease caused by incompetence of immune function |
| DE3348493A DE3348493C2 (en) | 1982-05-28 | 1983-05-25 | Di:hydro-poly:prenyl alcohol and ester and ether derivs. |
| DE3348492A DE3348492C2 (en) | 1982-05-28 | 1983-05-25 | Di:hydro-poly:prenyl alcohol and ester and ether derivs. |
| GB08314419A GB2122610B (en) | 1982-05-28 | 1983-05-25 | A polyprenyl compound and a pharmaceutical composition containing a polyprenyl compound |
| DE3348500A DE3348500C2 (en) | 1982-05-28 | 1983-05-25 | beta, gamma-dihydropolyprenyl alcohol derivative |
| DE3318989A DE3318989C2 (en) | 1982-05-28 | 1983-05-25 | ß, gamma-dihydropolyprenyl alcohol derivatives and medicaments containing them and their use |
| SE8303013A SE461650B (en) | 1982-05-28 | 1983-05-27 | B-DIHYDROPOLYPRENYL ALCOHOL DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
| NL8301892A NL194300C (en) | 1982-05-28 | 1983-05-27 | Pharmaceutical composition containing a polyprenol as an active ingredient and polyprenols suitable for use therein. |
| DK239483A DK171640B1 (en) | 1982-05-28 | 1983-05-27 | Analogous Process for Preparation of Beta, Gamma-dihydro-polyprenyl Alcohol Derivatives |
| CA000429108A CA1310660C (en) | 1982-05-28 | 1983-05-27 | B, -dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound |
| CH2902/83A CH654823A5 (en) | 1982-05-28 | 1983-05-27 | ALCOHOL DERIVATIVES BETA, GAMMA-DIHYDROPOLYPRENYLIQUE AND PHARMACEUTICAL COMPOSITIONS CONTAINING A POLYPRENYLIC COMPOUND. |
| ES522789A ES8406992A1 (en) | 1982-05-28 | 1983-05-27 | Beta, gamma-dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound |
| AT0197283A AT389871B (en) | 1982-05-28 | 1983-05-30 | METHOD FOR PRODUCING BETA, GAMMA -DIHYDROPOLYPRENYL ALCOHOL DERIVATIVES |
| IT21364/83A IT1164256B (en) | 1982-05-28 | 1983-05-30 | BETA DERIVATIVES, ALPHA DIHYDROPOLIPRENYL ALCOHOL AND PHARMACEUTICAL COMPOSITION CONTAINING A POLYPRENYL COMPOUND |
| FR838308941A FR2527597B1 (en) | 1982-05-28 | 1983-05-30 | ALCOHOL B DERIVATIVES, G-DIHYDROPOLYPRENYLIC AND PHARMACEUTICAL COMPOSITION CONTAINING A POLYPRENYLIC COMPOUND |
| FR8317170A FR2532848B1 (en) | 1982-05-28 | 1983-10-27 | PHARMACEUTICAL COMPOSITION CONTAINING A POLYPRENYL DERIVATIVE |
| FR8317173A FR2532845B1 (en) | 1982-05-28 | 1983-10-27 | PHARMACEUTICAL COMPOSITION COMPRISING DOCOSANOL AS ACTIVE INGREDIENT |
| FR8317176A FR2532847B1 (en) | 1982-05-28 | 1983-10-27 | PHARMACEUTICAL COMPOSITION COMPRISING AS ACTIVE INGREDIENT 3,7,11,15-TETRAMETHYLHEXADECA-1-ENE-3-OL |
| FR8317169A FR2532843A1 (en) | 1982-05-28 | 1983-10-27 | PHARMACEUTICAL COMPOSITION COMPRISING PHYTOL OR ISOPHYTOL AS ACTIVE INGREDIENT |
| FR8317171A FR2532844B1 (en) | 1982-05-28 | 1983-10-27 | PHARMACEUTICAL COMPOSITION CONTAINING A POLYPRENYL COMPOUND |
| FR8317175A FR2532846B1 (en) | 1982-05-28 | 1983-10-27 | PHARMACEUTICAL COMPOSITION COMPRISING AS ACTIVE INGREDIENT 3,7,11,15 - TETRAMETHYL -1,6,10,14-HEXADECATETRAENE-3-OL |
| ES529753A ES8506567A1 (en) | 1982-05-28 | 1984-02-15 | Beta, gamma-dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound |
| ES529754A ES529754A0 (en) | 1982-05-28 | 1984-02-15 | A PROCEDURE FOR THE PREPARATION OF A DERIVATIVE OF AN ALCOHOL, -DIHYDROPOLYPRENYLIC |
| GB08508219A GB2159712B (en) | 1982-05-28 | 1985-03-29 | Containing a polyprenyl compound |
| GB08508216A GB2159055B (en) | 1982-05-28 | 1985-03-29 | Pharmaceutical compositions of 3,7,11,15-tetra-methylhexadec-1-en-3-ol |
| GB08508214A GB2159054B (en) | 1982-05-28 | 1985-03-29 | Pharmaceutical compositions of polyprenyl alcohols |
| GB08508220A GB2159713A (en) | 1982-05-28 | 1985-03-29 | Containing a polyprenyl compound |
| GB08508218A GB2159711B (en) | 1982-05-28 | 1985-03-29 | Containing a polyprenyl compound |
| GB08508215A GB2159709B (en) | 1982-05-28 | 1985-03-29 | Containing a polyprenyl compound |
| GB08508217A GB2159710B (en) | 1982-05-28 | 1985-03-29 | Containing a polyprenyl compound |
| US06/760,221 US4624966A (en) | 1982-05-28 | 1985-07-29 | β,γ-dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound |
| FR858513026A FR2569108B1 (en) | 1982-05-28 | 1985-09-02 | PHARMACEUTICAL COMPOSITION CONTAINING A POLYPRENYL COMPOUND |
| SE8801514A SE502923C2 (en) | 1982-05-28 | 1988-04-22 | Use of a polyprenyl compound for the preparation of protylactic / therapeutic agent for human and animal diseases due to defective immune system |
| SE8801515A SE502924C2 (en) | 1982-05-28 | 1988-04-22 | Pharmaceutical composition containing an effective amount of 3,7,11,15-tetramethyl-hexadeca-1-en-3-ol or 3,7,11,15-tetramethyl-1,6,10,14-hexadecatetraen-3-ol |
| SE8801513A SE502922C2 (en) | 1982-05-28 | 1988-04-22 | Use of a polyprenyl compound for the preparation of prophylactic / therapeutic agent for human and animal diseases due to defective immune system |
| US08/011,197 US5280048A (en) | 1982-05-28 | 1993-01-29 | β,γ-dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound |
| US08/584,145 US6111131A (en) | 1982-05-28 | 1996-01-11 | Beta, gamma-dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound |
| US08/601,489 US6288128B1 (en) | 1982-05-28 | 1996-02-14 | β,γ-dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound |
| US08/599,944 US5658958A (en) | 1982-05-28 | 1996-02-14 | β, γ-dihydropolyprenyl alcohol derivatives effective at mitigating stress in animals |
| NL9900009A NL9900009A (en) | 1982-05-28 | 2000-12-05 | Di:hydro-poly:prenyl alcohol and ester and ether derivs. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10620382A JPS58225014A (en) | 1982-06-22 | 1982-06-22 | Preventive and remedy for disease caused by incompetence of immune function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58225014A JPS58225014A (en) | 1983-12-27 |
| JPH026328B2 true JPH026328B2 (en) | 1990-02-08 |
Family
ID=14427601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10620382A Granted JPS58225014A (en) | 1982-05-28 | 1982-06-22 | Preventive and remedy for disease caused by incompetence of immune function |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58225014A (en) |
-
1982
- 1982-06-22 JP JP10620382A patent/JPS58225014A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58225014A (en) | 1983-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3318989C2 (en) | ß, gamma-dihydropolyprenyl alcohol derivatives and medicaments containing them and their use | |
| US4623641A (en) | Method of treating ulcers and erosions in the gastrointestinal system using PGI2 -methyl ester-beta cyclodextrin inclusion complexes | |
| EP0938900B1 (en) | Preventives/remedies for stomatitis | |
| JPH026326B2 (en) | ||
| WO1992004028A1 (en) | Antineoplastic effect potentiator and antineoplastic agent | |
| JPH026327B2 (en) | ||
| US3432602A (en) | Oral alkyl glycerol ether improvement in radiation,radiomimetic,or cytostatic tumor therapies | |
| JPH07506568A (en) | Use of existing drugs to treat diabetes | |
| JPH02172920A (en) | Antitumor agent | |
| JPS58225014A (en) | Preventive and remedy for disease caused by incompetence of immune function | |
| JPH0325405B2 (en) | ||
| CN115105467A (en) | Dichromate febrifugone oral liquid and preparation method thereof | |
| US3852454A (en) | Treatment of rheumatoid arthritis | |
| JPS5936615A (en) | Carcinostatic agent | |
| JPH09143085A (en) | Hepatotonic agent containing licorice component | |
| JPS5938206B2 (en) | Bronchial asthma treatment whose main ingredient is coenzyme Q | |
| CN107397810B (en) | Iron hydroxide-peach gum-based phosphorus binder, preparation method and application thereof | |
| JPH0372468A (en) | Triazole compound and antifungal agent containing the same | |
| JPH0623108B2 (en) | Tumor formation inhibiting composition | |
| JPH0349891B2 (en) | ||
| JPH02330B2 (en) | ||
| JPH0120128B2 (en) | ||
| CN113350370A (en) | Application of polyethylene glycol in preventing and/or treating tumor | |
| JPH06279445A (en) | Cancer metastasis suppressor | |
| CA2259997C (en) | Remedies and preventives for stomatitis |